Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Georgiamune Inc. logo — Georgiamune is reprogramming immune signaling pathways to re...

Georgiamune Inc.

Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fight diseases.

Founded 2014 United States Gaithersburg, United States 30 employees Series A Total: $75.00M Biotechnology, Health Care +1

General Information

Company Name Georgiamune Inc.
Founded Year 2014
Location United States Gaithersburg, United States
Founders / Decision Makers
Team member
Employees 30
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Georgiamune Inc.. To contact Georgiamune Inc., visit georgiamune.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Georgiamune Inc. compare?

A PDF of Georgiamune Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Georgiamune Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Georgiamune Inc.

Georgiamune Inc., founded in 2014, operates at the intersection of biotechnology, health care, and wellness. This U.S.-based clinical-stage immunotherapeutic biotechnology firm is driving innovation by reprogramming immune signaling pathways, a strategy aimed at redefining immune system responses to combat an array of diseases.

The company has garnered attention for its pioneering work in immune therapeutics targeting cancer and autoimmune diseases. By leveraging groundbreaking scientific discoveries, Georgiamune aims to restore immune balance, setting a new standard in therapeutic development.

Recently, the company secured a $75.00M Series A investment on 09 August 2023. This funding round included support from reputable investors such as BioVentures Investors, General Catalyst, Alexandria Venture Investments, Catalio Capital Management, Verition Fund Management, Parker Institute for Cancer Immunotherapy, and Mubadala Capital Ventures. Their backing signifies strong confidence in Georgiamune's potential to revolutionize immunotherapeutics.

Business keywords: immunotherapy, immune signaling pathways, clinical stage, cancer treatment, autoimmune diseases, immune therapeutics, scientific discovery, reprogramming immune system, disease fighting, immune balance, biopharmaceuticals

Services & Products

Reprogramming Immune Responses
Drug Design and Development
Preclinical Research
Pipeline Development

Target Customers

Healthcare Providers Oncologists Immunologists Patients with Cancer Patients with Autoimmune Diseases Biopharmaceutical Companies

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $75.00M 7
General Catalyst Alexandria Venture Investments Catalio Capital Management
General Catalyst, Alexandria Venture Investments +5
01 Aug 2023
Spinout Undisclosed 1
Augusta University
01 Jan 2018

Georgiamune Inc. Alternatives & Competitors

View All Alternatives
Georgiamune Inc. vs
Q32 Bio Inc.
Q32 Bio Inc. United States

Revolutionizing the future of targeted immune therapeutics

28 employees
Biotechnology, Health Care
Compare Georgiamune Inc. vs Q32 Bio Inc.
Georgiamune Inc. vs
Montis Biosciences
Montis Biosciences Belgium

Pioneering next-gen therapeutics to harness C1q's central role in neuroinflammatory diseases.

14 employees
Biotechnology, Health and Wellness
Compare Georgiamune Inc. vs Montis Biosciences
Georgiamune Inc. vs
Repertoire Immune Medicines
Repertoire Immune Medicines United States

Repertoire is a biotechnology company creating a new category of immune medicines for cancer and aut...

Series B
86 employees
Biotechnology, Health and Wellness
Also compare with: Georgiamune Inc. vs Adaptive Biotechnologies Corp. Adaptive Biotechnologies Corp. View all alternatives

FAQ About Georgiamune Inc.

Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fight diseases.
Georgiamune Inc. was founded in 2014.
Georgiamune Inc. is headquartered in Gaithersburg, United States.
Georgiamune Inc. operates in Biotechnology, Health Care and Health and Wellness. Its work centres on immunotherapy, immune signaling pathways, clinical stage and cancer treatment. Its customers include Healthcare Providers, Oncologists and Immunologists.
Georgiamune Inc. has approximately 30 employees.
Georgiamune Inc. has completed 2 funding rounds, raising a total of $75.00M. The latest funding stage is Series A.
Georgiamune Inc. offers: Reprogramming Immune Responses, Drug Design and Development, Preclinical Research, Pipeline Development.
Top alternatives and competitors to Georgiamune Inc. include Q32 Bio Inc., Montis Biosciences, Repertoire Immune Medicines, Asylia Therapeutics, 3T Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Georgiamune Inc. and Q32 Bio Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Georgiamune Inc., https://bouncewatch.com/company/georgiamune-inc, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout